Eric Swayze Biography and Net Worth

Dr. Swayze is executive vice president of Research at Ionis Pharmaceuticals. He is responsible for leading preclinical antisense drug discovery and antisense technology research.

Previously, Dr. Swayze was vice president of Chemistry and Neuroscience Drug Discovery at Ionis, overseeing the advancement of multiple programs to clinical development. He joined Ionis in 1994 and has contributed to key technology advancements, including Ionis' Generation 2.5 chemistry and Ligand-Conjugated Antisense (LICA) technology.

He is an author on more than 150 scientific manuscripts, several reviews and book chapters, and is an inventor of more than 140 issued US patents. He received his Ph.D. in Organic Chemistry at the University of Michigan under the guidance of Professor Leroy B. Townsend.

What is Eric Swayze's net worth?: The estimated net worth of Eric Swayze is at least $1.55 million as of January 31st, 2025. Dr. Swayze owns 48,017 shares of Ionis Pharmaceuticals stock worth more than $1,549,509 as of March 26th. This net worth estimate does not reflect any other assets that Dr. Swayze may own. Additionally, Dr. Swayze receives an annual salary of $1,010,000.00 as EVP at Ionis Pharmaceuticals. Learn More about Eric Swayze's net worth.
How old is Eric Swayze?: Dr. Swayze is currently 58 years old. There are 6 older executives and no younger executives at Ionis Pharmaceuticals. The oldest executive at Ionis Pharmaceuticals is Ms. B. Lynne Parshall Esq., J.D., Director, who is 70 years old. Learn More on Eric Swayze's age.
What is Eric Swayze's salary?: As the EVP of Ionis Pharmaceuticals, Inc., Dr. Swayze earns $1,010,000.00 per year. There are 2 executives that earn more than Dr. Swayze. The highest earning executive at Ionis Pharmaceuticals is Dr. Brett P. Monia Ph.D., Founder, CEO & Director, who commands a salary of $2,380,000.00 per year. Learn More on Eric Swayze's salary.
How do I contact Eric Swayze?: The corporate mailing address for Dr. Swayze and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at wwalke@ionisph.com. Learn More on Eric Swayze's contact information.
Has Eric Swayze been buying or selling shares of Ionis Pharmaceuticals?: During the last ninety days, Eric Swayze has sold $279,105.13 in Ionis Pharmaceuticals stock. Most recently, Eric Swayze sold 1,367 shares of the business's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $32.31, for a transaction totalling $44,167.77. Following the completion of the sale, the executive vice president now directly owns 48,017 shares of the company's stock, valued at $1,551,429.27. Learn More on Eric Swayze's trading history.
Who are Ionis Pharmaceuticals' active insiders?: Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Michael Hayden (Director), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?: During the last year, Ionis Pharmaceuticals insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $181,100.00. During the last year, insiders at the sold shares 18 times. They sold a total of 144,589 shares worth more than $5,063,297.91. The most recent insider tranaction occured on March, 11th when CEO Brett P Monia sold 140 shares worth more than $4,524.80. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.
Information on this page was last updated on 3/11/2025.

Eric Swayze Insider Trading History at Ionis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/31/2025	Sell	1,367	$32.31	$44,167.77	48,017
1/16/2025	Sell	7,154	$32.84	$234,937.36	45,670
11/12/2024	Sell	1,194	$37.92	$45,276.48	33,713
10/16/2024	Sell	53	$38.31	$2,030.43	157
2/2/2024	Sell	1,907	$49.56	$94,510.92	34,324
1/31/2024	Sell	10,773	$52.00	$560,196.00	32,516
10/17/2023	Sell	52	$47.95	$2,493.40	73
2/6/2023	Sell	1,815	$40.79	$74,033.85	31,941
1/18/2023	Sell	5,631	$39.74	$223,775.94	30,041
9/8/2022	Sell	460	$44.55	$20,493.00	19,892
4/21/2022	Sell	378	$44.15	$16,688.70	20,353
1/5/2021	Sell	195	$55.99	$10,918.05	5,107

Eric Swayze Buying and Selling Activity at Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $31.42

$31.04

$32.33

50 Day Range

MA: $32.58

$30.35

$34.75

2 Week Range

Now: $31.42

$30.23

$52.34

Volume

502,997 shs

Average Volume

1,419,841 shs

Market Capitalization

$4.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28

Eric Swayze Biography and Net Worth

What is Eric Swayze's net worth?

How old is Eric Swayze?

What is Eric Swayze's salary?

How do I contact Eric Swayze?

Has Eric Swayze been buying or selling shares of Ionis Pharmaceuticals?

Who are Ionis Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Ionis Pharmaceuticals?